Table of Contents

company-logo

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Dividend Announcement

• Blueprint Medicines does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Blueprint Medicines dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Blueprint Medicines Dividend History

Blueprint Medicines Dividend Yield

Blueprint Medicines current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Blueprint Medicines stock? Use our calculator to estimate your expected dividend yield:

Blueprint Medicines Financial Ratios

P/E ratio-46.46
PEG ratio-0.46
P/B ratio19.00
ROE-47.66%
Payout ratio0.00%
Current ratio3.32
Quick ratio3.27
Cash Ratio0.35

Blueprint Medicines Dividend FAQ

Does Blueprint Medicines stock pay dividends?
Blueprint Medicines does not currently pay dividends to its shareholders.
Has Blueprint Medicines ever paid a dividend?
No, Blueprint Medicines has no a history of paying dividends to its shareholders. Blueprint Medicines is not known for its dividend payments.
Why doesn't Blueprint Medicines pay dividends?
There are several potential reasons why Blueprint Medicines would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Blueprint Medicines ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Blueprint Medicines has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Blueprint Medicines a dividend aristocrat?
Blueprint Medicines is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Blueprint Medicines a dividend king?
Blueprint Medicines is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Blueprint Medicines a dividend stock?
No, Blueprint Medicines is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Blueprint Medicines stocks?
To buy Blueprint Medicines you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Blueprint Medicines stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.